“According to a new report published by Introspective Market Research, Cell and Gene Therapy Market by Therapy Type, Delivery Method, and Application, The Global Cell and Gene Therapy Market Size Was Valued at USD 25.31 Billion in 2023 and is Projected to Reach USD 270.64 Billion by 2032, Growing at a CAGR of 30.12% from 2024 to 2032.”

The Cell and Gene Therapy Market represents a transformative segment of the global healthcare industry, offering innovative treatment approaches that target the root cause of diseases rather than managing symptoms. These therapies involve modifying genes or cells to treat, prevent, or potentially cure a wide range of genetic disorders, cancers, and chronic diseases. Compared to conventional treatments, cell and gene therapies provide long-term efficacy, precision medicine benefits, and reduced recurrence rates.

The market has witnessed significant advancements driven by rapid progress in biotechnology, genomic research, and regenerative medicine. Increasing approvals of advanced therapy medicinal products (ATMPs), rising investments from pharmaceutical companies, and expanding clinical trial pipelines have accelerated market adoption. Moreover, supportive regulatory frameworks and growing collaboration between biotech firms and research institutes are strengthening innovation.

Major end-use industries include hospitals, specialty clinics, and research organizations, with oncology, rare genetic disorders, and autoimmune diseases being key therapeutic areas. As healthcare systems shift toward personalized medicine, the demand for cell and gene therapies is expected to surge globally.

Market Segmentation

The Cell and Gene Therapy Market is segmented into Therapy Type, Delivery Method, and Application.
By Therapy Type, the market is categorized into Gene Therapy, Cell Therapy, and Gene-Modified Cell Therapy.
By Delivery Method, the market is categorized into Viral Vectors, Non-Viral Vectors, and Ex Vivo Delivery.
By Application, the market is categorized into Oncology, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, and Others.

Growth Driver

One of the primary growth drivers of the Cell and Gene Therapy Market is the rising prevalence of cancer and rare genetic disorders worldwide. Conventional treatments often fail to provide long-term remission for these conditions, creating a strong demand for advanced therapeutic alternatives. Cell and gene therapies offer targeted, personalized treatment options with improved clinical outcomes. Additionally, increasing R&D funding, technological advancements in gene editing tools such as CRISPR-Cas9, and favorable reimbursement policies in developed regions are significantly accelerating market growth.

Market Opportunity

A major market opportunity lies in the expanding application of cell and gene therapies in emerging economies. Improving healthcare infrastructure, growing awareness of advanced therapies, and increasing government initiatives to promote biotechnology research are opening new growth avenues. Furthermore, the development of scalable manufacturing processes and cost-efficient production techniques is expected to improve accessibility. Strategic partnerships, licensing agreements, and pipeline expansion into non-oncology indications also present lucrative opportunities for market players.

Detailed Segmentation

Cell and Gene Therapy Market, Segmentation The Cell and Gene Therapy Market is segmented on the basis of Therapy Type, Indication, and End-User.

Therapy Type

The Therapy Type segment is further classified into Cell Therapy and Gene Therapy. Among these, the Cell Therapy sub-segment accounted for the highest market share in 2023. This dominance is largely attributed to the remarkable success of CAR-T cell therapies in treating hematological malignancies. Cell therapies are highly effective in repairing and regenerating damaged tissues, making them a cornerstone for advanced oncology treatments. The segment’s growth is fueled by continuous clinical advancements in immune cell therapies and stem cell applications, which offer durable responses for patients who have failed traditional lines of treatment, thereby securing a leading position in the therapeutic landscape.

Indication

The Indication segment is further classified into Oncology, Genetic Disorders, Cardiovascular Diseases, and Neurological Disorders. Among these, the Oncology sub-segment accounted for the highest market share in 2023. The high incidence of cancer globally and the limitations of conventional therapies like chemotherapy and radiation have made oncology the primary focus for cell and gene therapy development. Significant R&D investments are directed toward creating therapies that can precisely target tumor cells without damaging healthy tissue. The approval of several CAR-T products specifically for blood cancers has solidified this segment's lead, as it continues to drive the highest volume of clinical trials and commercial revenue.

Some of The Leading/Active Market Players Are-

• Novartis AG (Switzerland)
• Gilead Sciences, Inc. (USA)
• Bristol Myers Squibb (USA)
• Roche Holding AG (Switzerland)
• Pfizer Inc. (USA)
• Bluebird Bio, Inc. (USA)
• Sarepta Therapeutics, Inc. (USA)
• Vertex Pharmaceuticals Incorporated (USA)
• Amgen Inc. (USA)
• UniQure N.V. (Netherlands)
• Orchard Therapeutics (UK)
• Sangamo Therapeutics (USA)
• CRISPR Therapeutics (Switzerland)
• Adaptimmune Therapeutics (UK)
• Fate Therapeutics (USA)
and other active players.

Key Industry Developments

In March 2024, a leading biotechnology company received regulatory approval for a next-generation gene therapy targeting a rare inherited disorder.
This approval marked a significant milestone, expanding the company’s commercial portfolio and reinforcing confidence in advanced genetic treatment platforms.

In September 2023, a major pharmaceutical firm announced a strategic partnership with a biotech startup to co-develop cell-based oncology therapies.
The collaboration aims to accelerate clinical development timelines, enhance manufacturing capabilities, and broaden the therapeutic pipeline.

Key Findings of the Study

• Gene-modified cell therapy dominates the therapy type segment
• Viral vectors remain the preferred delivery method
• North America leads the global market share
• Rising cancer prevalence is a key growth driver
• Personalized medicine trends are shaping future demand

More Info:- https://introspectivemarketresearch.com/reports/cell-and-gene-therapy-market/

About Us

At Introspective Market Research Private Limited, we are a forward-thinking research consulting firm committed to driving growth in the Cell and Gene Therapy Market. With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global Hormone Replacement Therapy Market industry.

📞 Contact Us

Introspective Market Research Pvt. Ltd.
Phone: +91-91753-37569
Email: sales@introspectivemarketresearch.com
Web: www.introspectivemarketresearch.com